A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.

NCT00531804 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: gantenerumab

Sponsor

Hoffmann-La Roche